Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:CSCI - Post by User

Comment by Hopeforthebeston Sep 24, 2024 2:32pm
97 Views
Post# 36238843

RE:RE:RE:New Press Release - COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

RE:RE:RE:New Press Release - COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development ProgramsStinzo,

Just like with the garbage they pedalled with the merger of equals where they fed us the bull about doing an exhaustive search for an equal partner, they will come out with this news release at the end of the year. "gilles gagnon is proud to announce that after an exhaustive search for his replacement CSCI BoD have approved "I am absolutely thrill, NOSHOWRONNIE to lead CSCI into the next phase. NOSHOWRONNIE will telecommunicate from his mansion in quebec in the summer and somewhere down south in the winter. With expected cash reserves of less than $1,000,000.00 after paying consulting fees to gilles gagnon and a mutuallly agreed upon bonus to both gagnon and NOSHOWRONNIE for several years the company, CSCI, will seize to exist after the summer of 2026. NOSHOWRONNIE main responsibility during this time is to ensure that all executives and BoD's are fairly and properly compensated."
<< Previous
Bullboard Posts
Next >>